Funding
Funding not disclosed
Founders
Product
Problem
Managing cancer often involves systemic treatments with significant off-target effects, leading to reduced quality of life. Current therapeutic approaches can also necessitate frequent clinic visits, disrupting patient routines and potentially delaying treatment adjustments.
Solution
Coherence has developed the SOMA platform, a closed-loop therapeutic neurotechnology designed for internal cancer management. This system comprises a wireless, coin-sized implant and an over-ear wearable device that continuously monitors patient data and delivers personalized bioelectronic stimulation. The platform leverages AI to learn from real-time physiological signals, enabling it to adapt therapy dynamically and target cancer at its bioelectric source. This approach aims to provide localized treatment with reduced systemic impact, facilitating home-based care and improving patient compliance and dignity.
Target Audience
The primary target audience includes patients undergoing cancer treatment, particularly those with glioblastoma, and their clinical care teams seeking advanced, localized therapeutic options.
Features
- Implantable, wireless neurotechnology device (7 x 13 mm) for precise placement during existing procedures.
- Up to 16 ultrathin, biocompatible threads extending from the implant for localized electrical stimulation and activity measurement.
- Over-ear wearable unit that wirelessly powers the implant, manages data, and executes stimulation protocols via inductive coupling.
- Contactless wireless charging dock for the wearable device, supporting daily use.
- Mobile application providing real-time data visualization, session history, and symptom tracking capabilities.
- Clinician portal for remote monitoring of therapy, symptoms, and disease state, with options for remote therapy fine-tuning or autonomous AI-driven adaptation.
- MRI-transparent implant design to allow for unimpeded diagnostic imaging.
- AI and machine learning backend for decoding electrical signals, identifying tumor characteristics, and personalizing therapeutic waveforms.